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Abstract To evaluate the impact of rituximab on patient-
reported outcomes (PROs) in a US-based observational cohort
of patients with rheumatoid arthritis (RA). Patients with active
RA, prior exposure to ≥1 tumor necrosis factor inhibitor
(TNFi) and who newly initiated rituximab were identified.
Changes in PROs were assessed 1 year after rituximab initia-
tion. PRO measures included Clinical Disease Activity Index
(CDAI); patient global disease activity, pain and fatigue (vi-
sual analog score; 0–100); morning stiffness (hours); modified
Health Assessment Questionnaire (mHAQ; 0–3); and
EuroQoL EQ-5D. Of the 667 patients who newly initiated
rituximab, baseline PRO and clinical measures indicated that
patients were substantially impacted by their RA disease and
quality of life; 54% of patients had high disease activity. One
year after rituximab initiation, 49.0, 47.1, 49.8, and 23.2% of
patients reported clinically meaningful improvements in pa-
tient global, pain, fatigue, and mHAQ, respectively. Morning
stiffness and EuroQol EQ-5D domains improved in 48 and
19–32% of patients, respectively. These real-world registry
data demonstrated that patients with long-standing, refractory
RA experienced improvements in PROs 1 year after initiating
rituximab.
Keywords Biologics . Patient-reported outcomes .
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Introduction
Patients with rheumatoid arthritis (RA) often experience re-
duced health-related quality of life (HRQOL), including dis-
ability and RA-related comorbidities [1, 2]. The goals of treat-
ment in RA are to achieve low disease activity (LDA) or
remission and to improve HRQOL.
Patient-reported outcomes (PROs) include HRQOL indi-
ces, such as the ability to perform day-to-day tasks, emotional
health, and the degree of pain and discomfort. PROs are in-
creasingly being recognized as important measures in deter-
mining response to therapy in patients with RA [3–5].
Rituximab is a monoclonal antibody that targets and de-
pletes CD20+ B cells and, in combination with methotrexate,
is approved for the treatment of RA in patients who have had
an inadequate response to ≥1 tumor necrosis factor inhibitor
(TNFi). Limited data exist on the effect of rituximab on PROs
in real-world clinical settings. This study examined the impact
of rituximab on PROs in a US observational cohort of patients
with RA.
Methods
Study setting
The Corrona RA Registry is an independent, prospec-
tive, observational cohort of patients with RA [6, 7].
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Patients are recruited from 169 private and academic
practice sites across 40 states in the USA, with 656
participating rheumatologists. As of June 20, 2016, data
on 43,099 patients with RA have been collected. The
protocol was approved by the New England institutional
review board (IRB; #120160610) and the local IRBs of
participating academic sites. Registration number:
NCT01402661.
Study analysis population
Adult patients with RA who initiated rituximab for the
first t ime within Corrona from March 2006 to
September 2015 were identified. Eligible patients had
available PRO measurements at baseline (around the
time of rituximab initiation) and 1 year (9–15 months)
after rituximab initiation. All patients had previously
received ≥1 TNFi and had low, moderate, or high dis-
ease activity based on Clinical Disease Activity Index
(CDAI), defined as CDAI >2.8.
Assessments and outcomes
CDAI was assessed at 1 year and evaluated by the
median change from baseline and by the proportion of
patients achieving LDA/remission (CDAI ≤10). PROs
were assessed at 1 year and included the median change
from baseline and the proportion of patients reporting
minimum clinically important differences (MCIDs; de-
fined as improvement of ≥10) in patient global assess-
ment of disease, pain, and fatigue (0–100 on a visual
analog scale) [8]; improvement in morning stiffness (du-
ration in hours); proportion of patients achieving a clin-
ically meaningful improvement in modified Health
Assessment Questionnaire (mHAQ), defined as a de-
crease of >0.25 from baseline in the mHAQ score [9];
and improvement in the EuroQol EQ-5D overall health
status index, which records patient-reported HRQOL
across five domains (walking, self-care, usual activities,
pain/discomfort, and anxiety/depression). EuroQol EQ-
5D results are examined using a summary index (0–1)
or by individual evaluation of each domain [10].
Improvement in EQ-5D domains was defined as the
proportion of patients with any improvement or resolu-
tion of impairment among patients who reported impair-
ment at baseline.
PROs and CDAI were evaluated for both the overall
cohort and in patient populations stratified by number of
prior TNFis (1 or ≥2 prior TNFis). For patients with ≥2
visits within the time frame for the 12-month visit, the
visit closest to 12 months was used.
Statistical analysis
Comparisons between the 1 and ≥2 prior TNFi groups were
performed using χ2, t, or nonparametric equality-of-medians
tests, as appropriate. Responses for the outcome measures
were available for >95% of patients during the time when
the variables were part of the data collection process; patients
with missing data were excluded from outcome analyses.
Results
Patient demographics and baseline PROs
A total of 667 patients were included (Supplemental Fig. 1);
284 (42.6%) had received 1 prior TNFi, and 383 (57.4%) had
received ≥2 prior TNFis. Most patients were female (78.7%),
and the overall median age was 59 (interquartile range [IQR],
50–66) years (Table 1). The median duration of RA was 13
(IQR, 7–21) years, and 53.8% of patients had high disease
activity (CDAI >22) at baseline. Significantly higher propor-
tions of patients with ≥2 prior TNFis had received ≥1 non-
TNFi biologic (53.8 vs 39.1%) and were in high disease ac-
tivity (CDAI >22; 58.2 vs 47.9%) than patients with 1 prior
TNFi.
Patients were substantially impacted by their RA at base-
line. Overall, baseline median (IQR) scores for patient global
assessment, pain, and fatigue were 40 (25–60), 60 (31–75),
and 65 (40–80) mm, respectively (Table 1). The baseline me-
dian mHAQ score was 0.6 (IQR, 0.3–1), and patients reported
a median of 1 (IQR, 0.5–2) hour of morning stiffness. Most
patients reported at least some problems in the EQ-5D cate-
gories of walking (75.7%), usual activities (81.1%), and pain/
discomfort (95.8%). Almost one-half of all patients reported at
least some problems in self-care (48.6%) and anxiety/
depression (49.0%). Baseline PRO scores were mostly similar
between patients who had received 1 or ≥2 prior TNFis, with
the exception of fatigue and morning stiffness.
Rituximab persistency
Overall, 78.9% of patients persisted on rituximab through
1 year, whereas 21.1% switched to another biologic before
1 year. Among all patients, 63.3% received rituximab
retreatment and did not switch to another biologic, and
15.6% did not receive rituximab retreatment but also did not
switch to another biologic (Supplemental Table 1).
Improvement in CDAI and PROs 1 year after rituximab
initiation
The median improvement in CDAI from baseline to 1 year
was 8 (IQR, 17.8); results were similar between patients with
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1 or ≥2 prior TNFis. Overall, 30.4% of patients achieved
CDAI LDA/remission (CDAI ≤10) at 1 year. A significantly
higher proportion of patients with 1 prior TNFi achieved
CDAI LDA/remission than patients with ≥2 prior TNFis
(37.7 vs 25.1%, respectively; P < 0.001).
Improvement from baseline was observed in all PRO
measures at 1 year. The overall median (IQR) scores of
patient global assessment, pain, and fatigue improved by
7 (35), 7 (30), and 9 (25) mm, respectively. The propor-
tions of patients with improvements ≥MCID in patient
global assessment, pain, and fatigue were 49.0, 47.1, and
49.8%, respectively (Fig. 1a). Clinically meaningful im-
provement in mHAQ was reported in 23.2% of patients
(Fig. 1b). Almost one-half of all patients (48.3%) reported
some improvement in morning stiffness, with 19.8%
reporting a reduction in the duration of morning stiffness
of >60 min (Fig. 1c).
Patients also experienced improvement in all EQ-5D do-
mains at 1 year; among patients who reported problems at
baseline, 19% of patients reported at least some improvement
in walking, 30% in self-care, 24% in usual activities, 23% in
pain/discomfort, and 32% in anxiety/depression (Fig. 2).
Among patients who reported problems at baseline, 19% of
patients reported no problems in walking, 27% in self-care,
18% in usual activities, 11% in pain/discomfort, and 32% in
anxiety/depression. Similar improvements were observed be-
tween patients who received 1 prior TNFi and those who
received ≥2 prior TNFis.
Table 1 Baseline patient demographics, clinical characteristics, disease activity, and PRO measures
Total
N = 667
1 Prior TNFi
n = 284
≥2 Prior TNFis
n = 383
P valuea
Demographics and clinical characteristics
Age, median (IQR), years 59 (50–66) 60 (52–69) 58 (49–65) 0.013
Female, n (%) 525 (78.7) 223 (78.5) 302 (78.9) 0.918
White, n (%) 582 (87.3) 241 (84.9) 341 (89) 0.110
Duration of RA, median (IQR), years [n] 13 (7–21)
[664]
11 (6–22)
[281]
14 (7–27)
[383]
0.071
History of cardiovascular disease, n (%) 42 (6.3) 17 (6.0) 25 (6.5) 0.776
History of diabetes, n (%) 61 (9.1) 26 (9.2) 35 (9.1) 0.994
History of hyperlipidemia, n/N (%) 22/317 (6.9) 10/129 (7.8) 12/188 (6.4) 0.638
RF seropositive, n/N (%) 290/395 (73.4) 123/164 (75.0) 167/231 (72.3) 0.549
No. of prior nonbiologic DMARDs, median (IQR) 1 (0–2) 1 (0–2) 2 (1–3) <0.001
No. of prior non-TNFi biologics, %
0 350 (52.5) 173 (60.9) 177 (46.2) 0.001
1 228 (34.2) 82 (28.9) 146 (38.1)
≥2 89 (13.3) 29 (10.2) 60 (15.7)
CDAI score, n (%)
Low (>2.8 and ≤10) 81 (12.1) 38 (13.4) 43 (11.2) 0.029
Moderate (>10 and ≤22) 227 (34.0) 110 (38.7) 117 (30.5)
High (>22) 359 (53.8) 136 (47.9) 223 (58.2)
HRQOL measures, median (IQR) [n]
Patient global assessment (0–100) 40 (25–60)
[667]
40 (24.5–55)
[284]
40 (25–60)
[383]
0.302
Patient pain (0–100) 60 (31–75)
[667]
50 (25–75)
[284]
60 (36–75)
[383]
0.084
Patient fatigue (0–100) 65 (40–80)
[295]
55 (26–75)
[123]
70 (48.5–85)
[172]
0.014
mHAQ score (0–3) 0.6 (0.3–1)
[660]
0.6 (0.3–1)
[283]
0.8 (0.3–1)
[377]
0.094
Morning stiffness, hours 1 (0.5–2)
[650]
1 (0.5–2)
[277]
1.5 (0.5–2.8)
[373]
0.019
EQ-5D (0–1) 0.7 (0.6–0.8)
[274]
0.7 (0.6–0.8)
[114]
0.7 (0.6–0.8)
[160]
0.228
CDAI clinical disease activity index, DMARD disease-modifying antirheumatic drug, HRQOL health-related quality of life, IQR interquartile range,
mHAQmodified Health Assessment Questionnaire, PRO, patient-reported outcome,RA rheumatoid arthritis, RF rheumatoid factor, TNFi tumor necrosis
factor inhibitor
a The P value represents the comparison between patients who received 1 prior TNFi vs those who received ≥2 prior TNFis
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Fig. 1 Improvement in PROs (a), mHAQ (b), and duration of morning
stiffness (c)1 year after initiation of rituximab, overall and by prior TNFi
use. MCID minimum clinically important difference, mHAQ modified
Health Assessment Questionnaire, PRO patient-reported outcome, TNFi
tumor necrosis factor inhibitor. a MCIDs for patient global assessment,
pain, and fatigue were defined as median improvement from baseline to
1 year of ≥10 on a visual analog scale (0–100). b Meaningful improve-
ment in mHAQ score was defined as an improvement of >0.25.
Fig. 2 Improvement in EQ-5D
categories at 1 year among ritux-
imab initiators, overall and by
prior TNFi use. TNFi tumor ne-
crosis factor inhibitor. a
Percentage of patients reporting
improvement among patients who
reported difficulty in each mea-
sure at baseline. b Improvement
in the EQ-5D domains was de-
fined as either patients improving
from moderate to no disability or
those with severe disability im-
proving to moderate or no
disability
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Discussion
In this real-world cohort of patients with long-standing,
refractory RAwith active disease and prior TNFi exposure,
improvements were reported in all PROs 1 year after initi-
ation of rituximab. The overall median duration of RAwas
13 years; whereas all patients had prior TNFi exposure,
almost one-half (47.5%) had also received ≥2 prior non-
TNFi biologics. At baseline, 88% of patients had moderate
or high disease activity based on CDAI, and patients were
substantially impacted by their RA: most patients reported
p rob l ems w i t h wa l k i ng , u su a l a c t i v i t i e s , a nd
pain/discomfort, and almost one-half reported problems
with self-care and anxiety/depression. One year after initi-
ation of rituximab, 30% of patients achieved LDA/
remission (CDAI ≤10), and 49.0, 47.1, and 49.8% of pa-
tients achieved MCIDs in patient global, pain, and fatigue,
respectively. Among patients who had reported problems
at baseline, 11–32% reported no problems in walking, self-
care, usual activities, pain/discomfort, and anxiety/
depression at 1 year.
Clinical trials have also reported improvements in PROs
among patients with comparable disease duration and prior
use of TNFis; however, these studies reported different PRO
measures, including HAQ—disability index, Functional
Assessment of Chronic Illness Therapy—Fatigue, and Short
Form 36, 6 months after initiation of rituximab, limiting the
ability to directly compare our results with clinical trial results
[11, 12]. Real-world data on PROs in rituximab-treated pa-
tients with RA are limited. A recent open-label study of ritux-
imab in patients with long-standing RA showed that improve-
ment in PROs occurred early after initiation of rituximab,
plateaued at 12 weeks, and persisted through 24 weeks [13].
Although our study did not include PRO measures at time
points of <1 year, our findings suggest that the improvement
in PROs after rituximab initiation extends through 1 year.
This analysis is among the first to describe patient real-
world experience with rituximab treatment 1 year after initia-
tion. Patients in this observational cohort were treated and
followed consistent with routine care rather than based on a
mandated treatment protocol or visit schedule. Most patients
(≈80%) persisted with rituximab through 1 year. However,
because the follow-up period for this analysis was limited to
1 year, the long-term effect of rituximab, with or without
retreatment, on PROs could not be ascertained.
In conclusion, these results suggest that treatment with ri-
tuximab can improve HRQOL in addition to controlling or
improving underlying disease in patients with long-standing
RA previously treated with TNFis.
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